TMO Stock: Price, Earnings History and SEC Filings
Thermo Fisher Scientific Inc. (TMO) last traded at $697.00, down 1.72% on the latest session and up 3.3% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $6.68 against an analyst estimate of $6.40, a beat of 4.4%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TMO earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 21, 2026 | $6.68 | $6.40 | +4.37% |
| Jun 2026 | Jul 23, 2026 | $6.03 | $5.71 | +5.60% |
| Mar 2026 | Apr 23, 2026 | $5.44 | $5.20 | +4.62% |
| Dec 2025 | Jan 29, 2026 | $6.57 | $6.43 | +2.18% |
TMO beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How TMO reacts to earnings
Across its last 8 earnings releases, TMO moved 5.0% on average the next session, in either direction. It rose after 5 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-21 | Before open | +0.97% |
| 2026-07-23 | Before open | +8.71% |
| 2026-04-23 | Before open | -9.20% |
| 2026-01-29 | Before open | -2.61% |
| 2025-10-22 | Before open | +1.65% |
| 2025-07-23 | Before open | +9.14% |
| 2025-04-23 | Before open | -0.71% |
| 2025-01-30 | Before open | +6.78% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TMO financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $44.6B | $6.7B | $6.3B | 15.0% | $17.74 |
| 2024 | $42.9B | $6.3B | $7.3B | 14.8% | $16.53 |
| 2023 | $42.9B | $6.0B | $6.9B | 14.0% | $15.45 |
| 2022 | $44.9B | – | $6.9B | – | $17.63 |
| 2021 | $39.2B | – | $6.8B | – | $19.46 |
| 2020 | $32.2B | – | $6.8B | – | $15.96 |
| 2019 | $25.5B | – | $4.0B | – | $9.17 |
| 2018 | $24.4B | – | $3.8B | – | $7.24 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TMO
- 8-K · Oct 30, 2026Officer or director change
- 10-Q · Oct 30, 2026
- 8-K · Oct 21, 2026Results of operations, Financial statements and exhibits
- 10-Q · Jul 31, 2026
- 8-K · Jul 23, 2026Results of operations, Financial statements and exhibits
- 8-K · May 26, 2026Shareholder vote
- 10-Q · May 1, 2026
- 8-K · Apr 23, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 7, 2026
- 8-K · Mar 24, 2026Other events, Financial statements and exhibits
Insider filing activity
TMO insiders filed 24 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TMO news
- What Sent Illumina Stock Lower?Nov 2, 2026 · trefis.com
- Thermo Fisher Scientific (TMO) Stock Fair Value Rises After Q3 Beat And Higher GuidanceOct 31, 2026 · finance.yahoo.com
- How Investors Are Reacting To Thermo Fisher Scientific Stock After Strong Q3 EarningsOct 31, 2026 · finance.yahoo.com
- Global Human Papillomavirus (HPV) Genotyping Panels Market Report 2026 | Capitalize on NGS, AI and Self-Collection Through 2030 with Roche, Abbott, Thermo Fisher and QIAGENOct 30, 2026 · finance.yahoo.com
- Clinical Genomics Interpretation Platforms Global Market Report 2026 | Capitalize on AI and Cloud Growth Through 2030 with Thermo Fisher, Illumina, QIAGEN, and Tempus AIOct 30, 2026 · finance.yahoo.com
- Global Ribonucleic Acid (RNA) Interference Technology Market Report 2026-2030 | Capitalize on Precision Gene Silencing with Alnylam, Arrowhead, Silence Therapeutics, and RocheOct 30, 2026 · finance.yahoo.com
- Clinical Genomics Sequencing, Biobank, and Database Services Global Market to 2035 | Capitalize on AI and Precision Medicine: Illumina, Thermo Fisher, BGI Genomics, Tempus AIOct 30, 2026 · finance.yahoo.com
- Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex DiagnosticsOct 30, 2026 · finance.yahoo.com
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) is a US-listed public company on NYSE. The SEC classifies its business as Measuring & Controlling Devices NEC. It is incorporated in DE. Its fiscal year ends in December.